Do Not Be So Quick To Blame Microbes On The Lab, The US FDA Warns Emcure
Emcure's Hinjwadi, India, plant should have investigated other more likely sources of contamination more thoroughly, the FDA says.
You may also be interested in...
Court overrides stem cell clinic’s dismissal of drug GMPs, the US FDA upbraids drug makers for quality unit shortfalls, and a variety of snafus trigger drug recalls.
Emcure has launched a generic version of Eisai’s cancer drug Halaven on the Indian market at a sharp 40% discount to the innovator product, and hopes to expand patient access significantly.
Data integrity failures are so yesterday. Now it’s all about poor investigations into out-of-specification results.